# US 2026/0216325 A1 · Novel imidazopyrimidine compound and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216325 A1
- Document ID: US20260216325A1
- Status: Published application
- Kind: A1
- Application number: 19/146,280
- Filed: 2024-01-08
- Published: 2026-07-30
- Earliest claimed: 2023-01-09
- Assignees: Children's Medical Center Corporation; Dana-Farber Cancer Institute, Inc.
- Applicants: The Children's Medical Center Corporation; Dana-Farber Cancer Institute, Inc.
- Inventors: David J. Dowling; Ofer Levy; Dheeraj Soni; David A. Scott
- Web page: https://patentgrep.com/patent/US20260216325A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/06: for tuberculosis
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 33/06: Antimalarials
- A61P 35/04: specific for metastasis
- C07D 487/04: Ortho-condensed systems
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/575: {humoral response}
- A61K 2039/60: {characteristics by the carrier linked to the antigen}
- A61K 2039/70: {Multivalent vaccine}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure provides Compound (1), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Compound (1) is used as an enhancer and/or modifier of an immune response (e.g., innate and/or adaptive immune response), and is useful in treating and/or preventing a disease, as an adjuvant in a vaccine for a disease, (e.g., a proliferative disease, an inflammatory disease, an autoimmune disease, an infectious disease, an allergy, a fibrotic disease, a cardiovascular disease, a graft rejection, graft-versus-host disease, chronic disease, or addiction), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are vaccines, pharmaceutical compositions, kits, methods, and uses including or using Compound (1).

## Claims

### Claim 1

A compound of formula:
or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 3

A compound of formula:

### Claim 4 (depends on 1, 2, 3)

A pharmaceutical composition comprising the compound of any one of claims 1-3, and a pharmaceutically acceptable excipient.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4 further comprising an additional pharmaceutical agent.

### Claim 6 (depends on 1, 2, 3, 4, 5, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

A method of treating a disease in a subject in need thereof, the method comprising administering the compound of any of claims 1-3, the pharmaceutical composition of claim 4 or 5, the composition of any of claims 40-63, or the vaccine of any of claims 64-67.

### Claim 7 (depends on 6)

The method of claim 6, wherein the disease is a proliferative disease, an inflammatory disease, an autoimmune disease, an infectious disease, an allergy, a fibrotic disease, a cardiovascular disease, a graft rejection, graft-versus-host disease, chronic disease, or addiction.

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, wherein the disease is an infectious disease such as a viral infectious disease, sepsis, a pediatric infectious disease, a bacterial infectious disease, a mycobacterial infectious disease, a parasitic infectious disease, or a fungal infectious disease.

### Claim 9 (depends on 6, 7, 8)

The method of any of claims 6-8, wherein the disease is a bacterial infectious disease caused by infection with Streptococcus spp., Bordetella spp., Haemophilus influenzae type b, Neisseria spp., Vibrio spp., Yersinia spp., Staphylococci spp., or Salmonella spp.

### Claim 10 (depends on 6, 7, 8)

The method of any of claims 6-8, wherein the disease is a bacterial infectious disease that is anthrax, diphtheria, tetanus, or cholera.

### Claim 11 (depends on 6, 7, 8)

The method of any of claims 6-8, wherein the disease is a mycobacterial infectious disease caused by a tuberculosis infection or a non-tuberculous mycobacterial infection.

### Claim 12 (depends on 6, 7, 8)

The method of any of claims 6-8, wherein the disease is a viral infectious disease caused by adenovirus, polio virus, Ebola, herpes viruses (e.g., herpes simplex virus 1, herpes simplex virus 2, human herpesvirus 6, human herpesvirus 8), cytomegalovirus, varicella-zoster virus, measles, mumps, rubella, hepatitis A, hepatitis B, hepatitis C, human papilloma virus, influenza, parainfluenza virus, coronavirus (e.g., SARS-CoV-2), rabies, Japanese encephalitis, rotavirus, human immunodeficiency virus, respiratory syncytial virus, monkeypox, smallpox, yellow fever, or Zika Virus.

### Claim 13 (depends on 6, 7, 8)

The method of any of claims 6-8, wherein the disease is a parasitic infectious disease that is malaria or leishmaniasis.

### Claim 14 (depends on 6, 7)

The method of claim 6 or 7, wherein the disease is cancer.

### Claim 15 (depends on 6, 7, 8)

The method of any of claims 6-8, wherein the disease is a fungal infectious disease caused by Candida spp., Aspergillus spp., Cryptococcus spp., Mucoromycete, Blastomyces dermatitidis, Histoplasma capsulatum, or Sporothrix schenckii.

### Claim 16 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any of claims 6-15, wherein the composition is administered once to the subject.

### Claim 17 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any of claims 6-15, wherein the composition is administered repeatedly to the subject.

### Claim 18 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any of claims 6-17, wherein the composition is administered intradermally, intramuscularly, intravaginally, intravenously, intranasally, orally, subcutaneously, transdermally, topically, and/or sublingually.

### Claim 19 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any of claims 6-18, wherein the composition is administered as a prophylactic.

### Claim 20 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any of claims 6-19, wherein the composition is administered as a combination therapy with another immunomodulatory agent, an immunomodulating antibody, an immunomodulating biologic, or an inhibitor of molecular pathways that limits immune responses.

### Claim 21 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 6-20, wherein the subject is a human infant.

### Claim 22 (depends on 11)

The method of claim 11, wherein the human infant is less than or equal to 28 days of age, less than or equal to 4 days of age, less than or equal to 2 days of age, or less than or equal to 24 hours of age at the time of administration, or the administration occurs at birth.

### Claim 23 (depends on 22)

The method of claim 22, wherein a second administration occurs when the human infant is less than or equal to 28 days of age, or less than or equal to 6 months of age.

### Claim 24 (depends on 21)

The method of claim 21, wherein the administration occurs when the human infant is 2 months, 4 months, and 6 months of age.

### Claim 25 (depends on 21, 22, 23, 24)

The method of any of claims 21-24, wherein the infant is born prematurely or has low birth weight.

### Claim 26 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 6-20, wherein the subject is a pediatric human of up to 18 years of age.

### Claim 27 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 6-20, wherein the subject is a human adult.

### Claim 28 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 6-20, wherein the subject is a human adult of 65 years of age or older.

### Claim 29 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any of claims 6-28, wherein the subject is immunocompromised due to primary immunodeficiency, acquired immunodeficiency and/or distinct immunity.

### Claim 30 (depends on 1, 2, 3, 4, 5, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

A method of enhancing an immune response in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of any of claims 1-3, the pharmaceutical composition of claim 4 or 5, the composition of any of claims 40-63, or the vaccine of any of claims 64-67.

### Claim 31 (depends on 30)

The method of claim 30, wherein the immune response is an innate immune response.

### Claim 32 (depends on 30, 31)

The method of claim 30 or 31, wherein the compound activates peripheral blood mononuclear cells (PBMCs).

### Claim 33 (depends on 30, 31, 32)

The method of any of claims 30-32, wherein the compound activates one or more pattern recognition receptors (PRRs).

### Claim 34 (depends on 33)

The method of claim 33, wherein the PRR is a Toll-like receptor (TLR), a NOD-like receptor (NLR), a RIG-I-like receptor, a C-type Lectin receptor, or STING.

### Claim 35 (depends on 34)

The method of claim 34, wherein the Toll-like receptor is TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR9, and/or TLR10.

### Claim 36 (depends on 34)

The method of claim 34, wherein the Toll-like receptor is TLR7 and/or TLR8.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35, 36)

The method of any of claims 30-36, wherein the compound induces the production of immunomodulatory cytokines and/or chemokines in the subject.

### Claim 38 (depends on 35)

The method of claim 35, wherein the cytokines and chemokines include TNF, IL-12, IL-6, IL-10, or CXCL-8.

### Claim 39 (depends on 1, 2, 3, 4, 5, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

A kit comprising the compound of any of claims 1-3, the pharmaceutical composition of claim 4 or 5, the composition of any of claims 40-63, or the vaccine of any of claims 64-67; and instructions for use.

### Claim 40 (depends on 1)

A composition comprising an antigen and the compound of claim 1, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.

### Claim 41 (depends on 40)

The composition of claim 40, wherein the antigen comprises a protein or polypeptide.

### Claim 42 (depends on 40, 41)

The composition of claim 40 or 41, wherein the antigen comprises a nucleic acid encoding a protein or a polypeptide.

### Claim 43 (depends on 42)

The composition of claim 42, wherein the nucleic acid is DNA or RNA.

### Claim 44 (depends on 40, 41, 42, 43)

The composition of any of claims 40-43, wherein the antigen is from a microbial pathogen.

### Claim 45 (depends on 45)

The composition of claim 45, wherein the microbial pathogen is a bacterium, mycobacterium, fungus, virus, parasite, or prion.

### Claim 46 (depends on 45)

The composition of claim 45, wherein the microbial pathogen is a bacterium selected from the group consisting of Bacillus spp., Bordetella spp., Corynebacterium spp, Clostridium spp, Haemophilus spp., Streptococcus spp, Staphylococci spp., Mycobacterium spp., Neisseria spp., Salmonella spp., Vibrio spp., and Yersinia spp.

### Claim 47 (depends on 45)

The composition of claim 45, wherein the microbial pathogen is a virus selected from the group consisting of adenovirus, enterovirus (e.g., polio virus), Ebola virus, herpes viruses (e.g., herpes simplex virus 1, herpes simplex virus 2, human herpesvirus 6, human herpesvirus 8), cytomegalovirus, varicella-zoster, measles, mumps, rubella, hepatitis A virus, hepatitis B virus, hepatitis C virus, human papilloma virus, influenza virus, parainfluenza virus, coronavirus (e.g., SARS-CoV-2), rabies, Japanese encephalitis, rotavirus, human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), smallpox, monkeypox, yellow fever, and Zika Virus.

### Claim 48 (depends on 45)

The composition of claim 45, wherein the microbial pathogen is a parasite selected from the group consisting of Plasmodium spp., Leishmania, and a helminth.

### Claim 49 (depends on 45)

The composition of claim 45, wherein the microbial pathogen is a fungus selected from the group consisting of Candida spp., Aspergillus spp., Cryptococcus spp., Mucoromycete, Blastomyces dermatitidis, Histoplasma capsulatum, and Sporothrix schenckii.

### Claim 50 (depends on 40, 41, 42, 43)

The composition of any one of claims 40-43, wherein the antigen is a cancer-specific antigen.

### Claim 51 (depends on 50)

The composition of claim 50, wherein the antigen is a heteroclitic epitope or a cryptic epitope derived from the cancer-specific antigen.

### Claim 52 (depends on 50)

The composition of claim 50, wherein the cancer-specific antigen is a neoantigen.

### Claim 53 (depends on 40)

The composition of claim 40, wherein the antigen is a psychoactive substance or its hapten derivative (e.g., an opioid-specific antigen).

### Claim 54 (depends on 40)

The composition of claim 40, wherein the antigen is a hapten.

### Claim 55 (depends on 40)

The composition of claim 40, wherein the antigen comprises a lipopolysaccharide (LPS).

### Claim 56 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The composition of any of claims 40-55, further comprising a pharmaceutically acceptable carrier.

### Claim 57 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The composition of any of claims 40-56, wherein the composition is a vaccine composition.

### Claim 58 (depends on 57)

The composition of claim 57, wherein the compound is an adjuvant.

### Claim 59 (depends on 57, 58)

The composition of claim 57 or 58, wherein the antigen is adsorbed onto alum.

### Claim 60 (depends on 57, 58, 59)

The composition of any of claims 57-59, wherein the compound is adsorbed onto alum.

### Claim 61 (depends on 58, 59, 60)

The composition of any of claims 58-60, wherein the vaccine composition further comprises a second adjuvant.

### Claim 62 (depends on 61)

The composition of claim 61, wherein second adjuvant is an agonist of Pattern Recognition Receptors (PRRs) selected from the group consisting of Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptor, C-type Lectin receptors (CLRs), and a stimulator of interferon genes (STING).

### Claim 63 (depends on 61, 62)

The composition of claim 61 or 62, wherein second adjuvant is bound to or adsorbed to alum.

### Claim 64 (depends on 61, 62, 63)

The composition of any of claims 61-63, wherein the second adjuvant is alum.

### Claim 65 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

A vaccine comprising the composition of any of claims 40-64.

### Claim 66 (depends on 65)

The vaccine of claim 65, wherein the vaccine is a subunit vaccine, an attenuated vaccine, a conjugate vaccine, or an mRNA vaccine.

### Claim 67 (depends on 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

A method of enhancing an immune response to an antigen in a subject in need thereof, the method comprising administering to the subject an effective amount of the composition of any of claims 40-64.

### Claim 68 (depends on 67)

The method of claim 67, wherein the antigen and the compound are administered simultaneously.

### Claim 69 (depends on 67, 68)

The method of claim 67 or 68, wherein the antigen and the compound are administered separately.

### Claim 70 (depends on 67, 68, 69)

The method of any of claims 67-69, wherein the antigen and the compound are administered once to the subject.

### Claim 71 (depends on 67, 68, 69)

The method of any of claims 67-69, wherein the antigen and the compound are administered repeatedly to the subject.

### Claim 72 (depends on 67, 68, 69, 70, 71)

The method of any of claims 67-71, wherein the compound and/or the second adjuvant enhance antigen-presenting cell activity.

### Claim 73 (depends on 67, 68, 69, 70, 71, 72)

The method of any of claims 67-72, wherein the compound and/or second adjuvant activates B cell immunity.

### Claim 74 (depends on 67, 68, 69, 70, 71, 72, 73)

The method of any of claims 67-73, wherein the production of antigen-specific antibodies is increased, compared to when the antigen is administered alone.

### Claim 75 (depends on 67, 68, 69, 70, 71, 72, 73, 74)

The method of any of claims 67-74, wherein the activation of antigen-specific cytotoxic T cells is increased, compared to when the antigen is administered alone.

### Claim 76 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any of claims 67-75, wherein the compound polarizes the innate immune response toward T helper 1 (Th1) immunity, T helper 2 (Th2) immunity, T helper 17 (Th17) immunity, and/or T follicular helper (Tfh) cell immunity.

### Claim 77 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any of claims 67-76, wherein the compound prolongs the durability of protection in the subject against the antigen, compared to when the antigen is administered alone.

### Claim 78 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any of claims 67-77, wherein the compound increases the rate of an immune response compared to when the antigen is administered alone.

### Claim 79 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any of claims 67-78, wherein the compound achieves antigen dose sparing such that the antigen induces a same level of immune response at a lower dose in the presence of the compound, compared to when the antigen is administered alone.

### Claim 80 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any of claims 67-79, wherein the subject has or is at risk of developing an infectious disease.

### Claim 81 (depends on 80)

The method of claim 80, wherein the infectious disease is caused by a bacterium, a mycobacterium, a fungus, a virus, a parasite or a prion.

### Claim 82 (depends on 80, 81)

The method of claim 80 or 81, wherein the infectious disease is sepsis.

### Claim 83 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any of claims 67-79, wherein the subject has or is at risk of developing cancer.

### Claim 84 (depends on 83)

The method of claim 83, wherein the cancer is metastatic cancer.

### Claim 85 (depends on 83, 84)

The method of claim 83 or 84, wherein the cancer is melanoma.

### Claim 86 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 67-79, wherein the subject has or is at risk of developing allergy.

### Claim 87 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 67-79, wherein the subject has or is at risk of developing an addiction and/or death due to an overdose of a psychoactive substance.

### Claim 88 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method of any one of claims 67-87, wherein the administration is systemical or local.

### Claim 89 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The method of any one of claims 67-88, wherein the administration is intramuscular, intradermal, oral, intravenous, topical, transdermal, intranasal, intravaginal, or sublingual.

### Claim 90 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 67-89, wherein the administration is prophylactic.

### Claim 91 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 67-89, wherein the administration is therapeutic.

### Claim 92 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 67-89, wherein the subject is a human infant, an adult, or an older adult.

### Claim 93 (depends on 92)

The method of claim 92, wherein the subject is a human infant.

### Claim 94 (depends on 93)

The method of claim 93, wherein the human infant is less or equal to 28 days of age or less than or equal to 24 hours of age at the time of administration, or the administration occurs at birth.

### Claim 95 (depends on 94)

The method of claim 94, wherein a second administration occurs when the subject is less than or equal to 28 days of age or less than or equal to 6 months of age.

### Claim 96 (depends on 93)

The method of claim 93, wherein the administration occurs when the human infant is 2 months, 4 months, and 6 months of age.

### Claim 97 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 67-96, wherein the subject is born prematurely or has low birth weight.

### Claim 98 (depends on 92)

The method of claim 92, wherein the subject is a human adult.

### Claim 99 (depends on 92)

The method of claim 92, wherein the subject is an older adult.

### Claim 100 (depends on 99)

The method of claim 99, wherein the administration occurs when the subject is more than 65 years of age.

### Claim 101 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The method of any one of claims 67-100, wherein the subject is immunocompromised due to primary immunodeficiency, acquired immunodeficiency and/or distinct immunity.

### Claim 102 (depends on 60, 61, 62, 63, 64, 65, 66, 67)

A method of vaccinating a subject in need thereof, the method comprising administering to the subject an effective amount of the composition of any one of claims 60-63, or the vaccine of any one of claims 64-67.
